MRKR — Marker Therapeutics Cashflow Statement
0.000.00%
- $29.18m
- $13.11m
- $3.55m
Annual cashflow statement for Marker Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -41.9 | -29.9 | -8.24 | -10.7 | -12.2 |
| Depreciation | |||||
| Non-Cash Items | 6.98 | 5.98 | -11 | 0.246 | 0.538 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 5.47 | -5.81 | 2.85 | -0.425 | -0.388 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -27.3 | -27 | -16.4 | -10.9 | -12 |
| Capital Expenditures | -3.13 | -4.95 | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | 18.7 | — | — |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3.13 | -4.95 | 18.7 | — | — |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 52.6 | 0.202 | 1.11 | 15 | 9.86 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 22.1 | -31.7 | 3.33 | 4.08 | -2.15 |